Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045732 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02045732 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 4 participants.
The verdict
NCT02045732, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PF-06342674 0.25 mg/kg
- BIOLOGICAL PF-06342674 1.5 mg/kg
- BIOLOGICAL PF-06342674 6.0 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02045732
The ClinicalTrials.gov registry entry for NCT02045732 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02045732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02045732 about?
NCT02045732 is a clinical study titled "A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)". PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.
What is the current status of trial NCT02045732?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2014-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02045732?
The interventions under investigation include: Placebo (BIOLOGICAL), PF-06342674 0.25 mg/kg (BIOLOGICAL), PF-06342674 1.5 mg/kg (BIOLOGICAL), PF-06342674 6.0 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02045732?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.